## **Gemtesa (vibegron) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FI	MEMBER'S FIRST NAME:		
Instructions: Please fill out a important for the review (e. this form is Protected Health	g., chart notes or lab data,	to support the autho			
					URGENT
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:	FIRST NAME:		
PHONE NUMBER:		DATE OF BIRT	Н:		
STREET ADDRESS:					
CITY:		STATE:	ZIP CODE:	:	
PATIENT INSURANCE ID N	UMBER:	1			
MALE FEMALE HI	EIGHT (IN/CM):	WEIGHT (LB/KG):	ALLERG	IES:	
<u>—</u>					
IF YOU ARE NOT THE PATIENT OR THE PRES FOLLOWING LINK: <u>PRIMETHERAPEUTICS.CC</u>	*	HI DISCLOSURE AUTHORIZATION	FORM WITH THIS REC	QUEST WHICH CAN BE FOUND AT	T THE
	<b>.</b>				
PATIENT'S AUTHORIZED RE AUTHORIZED REPRESENTAT					
AUTHORIZED REPRESENTA	TIVE 3 PHONE NUIVIDER				
PRESCRIBER INFORMATIO	N				
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRE	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER	FAX NUMBER:		
STREET ADDRESS:					
CITY:	STATE:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTA	OFFICE CONTACT PERSON:		
MEDICATION OR MEDICA	L DISPENSING INFORMAT	ION			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	ILLS:	QUANTITY:	
NEW THERAPY	RENEWAL	IF RENEWAL:		/ INITIATED:	
DURATION OF THERAPY (S					

Continued on next page.



## Gemtesa (vibegron) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
□ Overactive Bladder		100 101
□ Other diagnosis:ICD	-10	
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A
Clinical Information:		
For Overactive Bladder, please fill out	t the following:	
Has the patient had a previous trial wates of trial.	rith generic oxybutyninIR/ER?   Yes	No Please submit documentation of
Has the patient had a previous trial wates of trial.	rith generic tolterodineIR/ER? 🗆 Yes 🗆	No Please submit documentation of
Has the patient had a previous trial w of trial.	rith generic solifenacin?   Yes   No   P	lease submit documentation of dates
Has the patient had a previous trial w trial.	rith generic darifenacin?   Yes   No Plant	ease submit documentation of dates of
Has the patient had a previous trial w dates of trial.	rith generic trospiumIR/ER? □ Yes □ No	Please submit documentation of
Does the patient have a contraindicate trospium?   Yes   No Please subr	tion that precludes the use of oxybutyni nit documentation.	n, tolterodine, solifenacin, darifenacin,
A) High risk for falls	of the following medical conditions? $\ \Box$ Y	'es □ No <i>Please circle</i> .
B) Concurrent potassium supple		
C) Diagnosis of dementia or other D) Parkinson's disease	er mental status changes	
D) Parkinson's disease E) Myasthenia Gravis		
F) Closed-angle glaucoma		
	lder AND has a diagnosis of atrial fibrilla	ation or other tachycardia
Has the patient had a previous trial wates of trial.	rith Myrbetriq(mirabegron)?   Yes   No	Please submit documentation of



## **Gemtesa** (vibegron) **Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
Does the patient have a contraindication the submit documentation	at precludes the use of Myrbetriq(mirabegron)? ☐ Yes ☐ No Please
Are there any other comments, diagnoses, s physician feels is important to this review?	symptoms, medications tried or failed, and/or any other information the
*Please note: Not all drugs/diagnoses are co information is received.	vered on all plans. This request may be denied unless all required
•	ided is true and accurate to the best of my knowledge. I understand that s designees may perform a routine audit and request the medical of the information reported on this form.
Prescriber Signature or Electronic I.D. Verific	cation: Date:
you are not the intended recipient, you are hereby not	ying this transmission contain confidential health information that is legally privileged. If if it is

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

